Mesoblast Limited Level 39 55 Collins Street Melbourne 3000 AUSTRALIA +61 3 9639 6036 Email:info@mesoblast.com
For media and shareholder inquiries: Julie Meldrum Corporate Communications Director E: julie.meldrum@mesoblast.com + 61 (0) 419 228 128
August 26 2010- Preliminary 2010 Annual Report
August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy
23 August 2010 - EGM documents - Letter from the Chairman, Notice of Meeting, Independent Expert Report.
16 August - Mesoblast on track for phase 3 bone marrow transplant trial following positive meeting with FDA
21 July - Mesoblast receives TGA regulatory approval to commercially manufacture adult stem cell products
12 July - Phase 3 meeting scheduled with FDA following positive results of bone marrow regeneration trial
28 May - Mesoblast featured at ASX Singapore conference highlighting emerging market leaders
19 May - United States FDA Clears Phase 2 Trial for Cervical Spinal Fusion
16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff
23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching
21 July 2010 - Southern Cross Equities Research – The clinical endgame nears
17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity
14 May 2010 - Bioshares
26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters
July 2009 - Chairman’s Letter
May 2009 - Chairman’s Letter
May 2008 - Issue Nine
© Copyright Mesoblast Limited 2010. All rights reserved. Website design by Infoprobe Australia
disclaimer | privacy policy
home | contact | sitemap | Angioblast Systems | webmail the company | the technology | product development | investor centre | news room
